Decabromodiphenyl oxide (DBDPO) and octabromobiphenyl (OBBP) perform well as fire-retardant additives for thermoplastics. Both compounds have low acute oral toxicity and low skin absorption toxicity. They are neither primary skin irritants or skin sensitizers and are only mildly irritating to the eyes. A 30-day dietary feeding study in rats established 8 mg DBDPO/kg-day as an unequivocal no-effect level and 80 mg/kg-day as a marginal effect level. A no-effect level was not established for OBBP in a comparative study. A 2-yr rat study providing 0.1 mg DBDPO/kg-day in the diet revealed the bromine concentration reached a plateau in the liver within 30 days, while the concentration in adipose tissue slowly increased. A comparable OBBP study revealed bromine concentration in the liver and adipose tissue increased steadily and rapidly with no attainment of a plateau during 180 days of the study. Neither compopnd produced an accumulation of bromine in other tissues. After administration of 14C DBDPO, all 4C activity was eliminated via the feces within 2 days. After administration of IC OBBP, 62% was eliminated with a half-life of less than 24 hr; the half-life for the remainder was greater than 16 days. In a teratology study, 10, 100, or 1000 mg DBDPO/ kg-day had no effect in rats. Reproductive capacity of rats was not effected at 3, 30, or 100 mg DBDPO/kg-day. No effects were observed on cytogenetic examination of bone marrow cells of parents and weanlings from the reproduction study.
Introduction
Flame retardancy is required for high performance thermoplastic resins because of their use in electrical and high temperature applications. Two compounds which meet stringent thermal stability requirements for these apapplications are decabromodiphenyl oxide (DBDPO) and octabromobiphenyl (OBBP). DBDPO has also found acceptance as a flameretardant (FR) agent for high-impact polystyrene, ABS, polyethylene, adhesives, thermoset polymer applications of epoxy resins, and unsaturated polyesters and in textile coating formulations. Since the toxicological properties of fire-retardant chemicals are a major factor in determining suitability for large scale use, the studies summarized in this paper were undertaken. The studies were intended to evaluate the toxicity of the materials and assess the potential hazards associated with their manufacture and use and to determine if these materials, like the structurally similar polychlorinated biphenyls, are absorbed and retained by the body.
Materials
The structure and properties of commercially produced decabromodiphenyl oxide (DBDPO) and octabromobiphenyl (OBBP) are summarized in Table 1 .
The composition of the OBBP and DBDPO EHP 11-22 Sprague-Dawley rats which were maintained on diets providing 800, 80, 8, or 0 mg of OBBP or DBDPO/kg-day. A 2-yr dietary feeding study in male and female rats providing dose levels of 1.0, 0.1, 0.01, or 0 mg of DBDPO./kg-day is on-going. A comparable study with OBBP was terminated after 8 months because of the likelihood that this material would bioaccumulate in the environment. Parameters monitored in the dietary feeding studies included the following: body weights, food consumption, appearance and demeanor, routine hematologic determinations, urinalysis, serum enzyme activity, organ weights, and gross and histopathological examination of tissues. In addition, at various times during a 2-yr period, tissues of rats receiving the aforementioned dietary levels of OBBP or DBDPO were analyzed for bromine by neutron activation analysis. Studies on the elimination of bromine from tissues were conducted on rats maintained for 90 days on diets containing 1.0 mg of OBBP or DBDPO/kg-day and then placed on a diet of untreated feed for designated periods up to 90 days for recovery. 14C-labeled OBBP or DBDPO, suspended in corn oil, was administered to male and female Sprague-Dawley rats at a dose of 1 mg/kg, and excretion of the radioactivity was measured at 24-hr intervals over a 16-day period. Radioactivity in various tissues of the 14C-OBBP-or 14C-DBDPO-treated rats was determined on days 1 1000, 100, 10, or 0 mg of DBDPO/kg, suspended in corn oil, caused no teratogenic response at any dose level. There were no indications of toxicity among the rats during gestation. The maternal body weights and food consumption of the DBDPO treated rats did not differ from control rats. The terminal liver weight of the DBDPOtreated rats, obtained at the time of cesarean section, were not different from those of the controls. Similarly, no differences were seen between the treated and control rats with respect to the position and number of fetuses in utero; the number of corpora lutea; individual pup weight, crown rump ratio and male/ female sex ratio. Significant incidences in resorptions occurred at the low dose levels but not at the high dose level.
No gross external abnormalities were seen in the fetuses from dams treated at any dose level of DBDPO. Soft tissue (4) and skeletal examinations (5) revealed an increased number of litters with subcutaneous edema and delayed ossification of normally developed bones of the skull of the fetuses of dams at the 1000 mg/kg level of DBDPO but not at the 100 mg/kg level.
Analysis of the maternal and fetal livers for 'bromine revealed statistically significant increased concentration in the livers of the maternal anmials receiving 1000 mg/kg-day of DBDPO. The concentrations in maternal livers at the two lower dose levels were not different from those of the controls. Likewise, there was no difference in the bromine concentration in the livers of the fetuses from dams receiving any dose level of DBDPO when compared with the controls.
Reproduction Study on DBDPO
The reproductive capacity of rats was not affected by diets providing 100, 30, or 3 mg/kgday of DBDPO given for 90 days prior to mating as well as during mating, gestation and lactation. The per cent and number of pregnancies, pup survival indices, neonatal body weights, male/female ratio on day 21, and the length of time between the first day of cohabitation and delivery were not affected by the inclusion of DBDPO in the diets. Furthermore, examination of the neonates at weaning revealed no treatment-related effects. Cytogenetic examination of bone marrow cells taken at necropsy from the femur of the treated parental animals as well as from the neonates at weaning showed no increase in cytogenetic aberrations when compared with controls.
Summary and Discussion of the Toxicological Investigations
Octabromobiphenyl and decabromodiphenyl oxide may be considered to present a low degree of hazard from acute exposure. Both experimental materials are low in acute oral toxicity. They are neither eye nor skin irritants nor skin sensitizers (3, 6) . OBBP and DBDPO are not absorbed through the skin (6) in acutely toxic amounts, and they do not possess bromacnegenic activity.
Dietary feeding studies conducted over a wide range of dose levels for 30 days to elucidate the potential hazard that might be incurred through long-term repeated exposure, resulted in an unequivocal "no-effect" level of 0.01 %o in the diet (approximately 8 mg/kg-day) for DBDPO, with a marginal effect level of 0. The no-effect level in this teratology study was 100 mg of DBDPO/kg-day. The number of resorptions occurring at the two lower levels of DBDPO was statistically greater than the controls. However, as this effect did not occur at the high dose level, it was probably due to chance rather than treatment.
Fetal toxicity in the form of subcutaneous edema was noted in fetuses of dams at the high dose level of DBDPO. The only other effect noted was delayed ossification of normally developed bones of the fetal skull occurring similarly at the high dose level.
Aftosmis et al. (7) have reported that OBBP administered in diets of pregnant rats caused a teratogenic response, gastroschisis, in some of the fetuses of dams on diets containing 0.1 and 1.0%o of OBBP. The bromine content was increased in the liver and fat of the OBBP treated maternal rats and also in the whole fetus.
The reproductivity of rats chronically maintained on diets containing DBDPO was unaffected at the highest dose level administered, 100 mg/kg-day. Inclusion of DBDPO in the diet had no detrimental effect on the resultant offspring and no cytogenetic effects were seen in parental or weanling bone marrow cells.
The data from the 30-day dietary feeding study and the teratology study indicate that the degree of hazard that exists from long-term exposure to DBDPO is significantly less than to OBBP. The 14C metabolism study, reproduction study, and the special studies on absorption, accumulation, and elimination, which were subsequently conducted, offer additional substantiation for this observation.
The results of the metabolism study show that the half-life for the disappearance of 14C activity from the body of DBDPO-treated rats was less than 24 hr. The disappearance of 14C activity from the body of OBBP-treated rats was biphasic. The half-life of the first phase was less than 24 hr, the second phase greater than 16 days. The principal route of excretion for both experimental materials was via the feces. No appreciable 14C activity (less than 1 %) was found in either urine or expired air. There were no sex-related differences in the way these materials were excreted by the rats.
Examination of the various tissues for radioactivity at 1, 3, and 16 days following administration of OBBP and DBDPO labeled with 14C revealed that absorption had occurred with both materials. The levels of 14C activity in the various tisues of the OBBP-treated rats were greater than those found in the corresponding tissues of DBDPO-treated rats. The 14C activity readily cleared from the tissues of the DBDPOtreated rats, whereas on day 16, the last day of the study, 14C activity persisted in the adrenal tissue, skin, adopose tissue, and heart of the OBBP-treated rats.
The results of the metabolism study further suggest that DBDPO does not have the potential of OBBP to bioaccumulate. The special tissue accumulation study revealed that after 180 days, there was no accumulation of OBBP or DBDPO in serum, kidney, skeletal muscle, or testes of rats on diets providing 0.1 mg/kgday. The sites of deposition were the liver and adipose tissue. The bromine content increased rapidly in both these tissues of the OBBPtreated rats. The bromine content of the livers of the DBDPO-treated rats reached a plateau after 30 days. The bromine concentration in the livers of the DBDPO-treated rats sacrificed after 180 days on tests were not statistically different from those of the controls. Analysis of the data on the bromine content in adipose tissue of DBDPO treated rats over a 12-month period revealed no accumulation in this tissue.
The special study on the elimination of bromine from various tissues of rats maintained for 90 days on diets providing 1.0 mg of OBBP or DBDPO/kg-day revealed high levels of bromine in the liver and adipose tissue of the OBBP-treated rats and low levels in the DBDPO-treated rats. Bromine was not eliminated from adipose tissue of the OBBP-treated rats and only partially eliminated from the liver of these rats after 90 days on recovery.
The low level of bromine in adipose tissue of the DBDPO-treated rats remained unaffected during the 90 days on recovery diets. The bromine concenration in the liver of these rats was not significantly higher than in the control livers after the first 10 days' recovery.
The in-depth toxicological investigation on DBDPO is continuing to be pursued by The Dow Chemical Company.
